Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 383

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 383
---
 2022 £’000 |   |     | 2021 £’000 |   |
| At 1 January                                                                              |     | –                  |     | –          |     |         71 |   |     |                    (197 | ) |     | –          |   |     |        (68 | ) |
| Transfers in the period from contract assets to trade receivables                         |     | –                  |     | –          |     |        (71 | ) |     |                       – |   |     | –          |   |     |          – |   |
| Amounts included in contract liabilities that was recognised as revenue during the period |     | –                  |     | –          |     |          – |   |     |                     197 |   |     | –          |   |     |         68 |   |
| Excess of revenue recognised over cash                                                    |     | –                  |     | –          |     |          – |   |     |                       – |   |     | –          |   |     |          – |   |
| Cash received in advance of performance and not recognised as revenue during the period   |     | –                  |     | –          |     |          – |   |     |                       – |   |     | (197       | ) |     |          – |   |
| At 31 December                                                                            |     | –                  |     | –          |     |          – |   |     |                       – |   |     | (197       | ) |     |          – |   |

The Group’s R&D
collaboration agreements are the delivery of services within the next 12 months for which the practical expedient in paragraph 121 (a)
of IFRS15 applies.

In 2023, all revenue
came from 1 customer (2022: 1 customer; 2021: 1 customer).

| Schedule of commercial segment |     |            |   |     |            |   |     |            |   |
|                                |     | 2023 £’000 |   |     | 2022 £’000 |   |     | 2021 £’000 |   |
| Customer A                     |     |        100 | % |     |        100 | % |     |        100 | % |

The Group contains one
reportable operating segment, Pipeline Research and Development (‘Pipeline R&D’). This segment seeks